BGI HEALTH (HK) C�OMPANY LIMITED

Name

BGI HEALTH (HK) C�OMPANY LIMITED

Legal name

BGI Health (HK) Company Limited

Website

https://hkbgi.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Clinical Genetic Testing and Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ)

akta.pro secondary industries

Genetic & Prenatal Testing Laboratories (HLAFAMAH), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

Keywords

• Non-invasive prenatal testing
• Genetic screening services
• Cancer genetic testing
• Newborn genetic screening
• Clinical DNA sequencing

Headquarters

HQ city

Hong Kong

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Laboratory Genetic Testing Services: Clinical laboratory testing services including NIFTY prenatal screening, VISTA carrier screening, SENTIS cancer genetic testing, and other genetic diagnostic tests performed in Hong Kong-certified laboratories
2. Self-Sampling Test Kits: Direct-to-consumer sales of self-sampling test kits including SENTIS HPV self-collection kits and COLOTECT colorectal cancer screening kits, sold online and through partner clinics

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

BGI Health (HK) runs a Hong Kong-certified clinical laboratory providing genetic and genomic testing services, including non-invasive prenatal screening (NIFTY/NIFTY PRO/NIFTY MONO), preconception and embryo genetic testing (VISTA), newborn screening (NOVA), clinical exome/genome sequencing (Xome), hereditary cancer panels (SENTIS), and self-sampling cancer screening kits (HPV and COLOTECT). The company also distributes the Umeta probiotic nutrition brand. Services are delivered through partner clinics and direct-to-consumer online channels.

Product overview

BGI Health (HK) Company Limited offers a comprehensive genetic testing portfolio under the BGI brand, comprising three main categories: reproductive health testing (NIFTY®/NIFTY PRO™/NIFTY® MONO non-invasive prenatal tests, VISTA™ carrier screening and chromosomal testing, NOVA™ newborn screening, Xome™ clinical sequencing), cancer detection (SENTIS™ hereditary cancer panels and HPV testing, COLOTECT™ colorectal cancer test), and nutrition products (Umeta probiotic line). The flagship NIFTY® series leverages cell-free DNA sequencing technology for prenatal screening, while SENTIS™ and COLOTECT™ provide consumer-accessible at-home testing kits for cancer risk assessment. The company operates a Hong Kong-certified laboratory and distributes through a network of partner clinics.

Differentiator

Problem solved

Functional benefit

Brands

• NIFTY: Non-Invasive Fetal TrisomY test - non-invasive prenatal testing for fetal chromosomal abnormalities
• NIFTY PRO
• NIFTY MONO
• VISTA
• NOVA
• BGI-XOME / Xome
• SENTIS
• COLOTECT
• Umeta (優美達)

Products and services

• NIFTY® Non-Invasive Prenatal Test Non-invasive prenatal test analyzing cell-free fetal DNA from a maternal blood sample to screen for fetal chromosomal abnormalities such as Down syndrome, Edwards syndrome, and Patau syndrome, marketed to pregnant women through Hong Kong partner clinics with sensitivity and specificity up to 99%.
• NIFTY PRO™ Non-Invasive Prenatal Test Enhanced non-invasive prenatal test expanding basic NIFTY screening to cover rare autosomal aneuploidies, 92 types of chromosomal microdeletions and microduplications, and additional findings across all 23 chromosome pairs, offered to pregnant women seeking more comprehensive fetal screening.
• NIFTY® MONO Single-Gene Disease Screening Non-invasive prenatal screening for fetal single-gene genetic diseases covering 202 conditions including skeletal, cardiac, and syndrome disorders caused by single-gene variants, used by pregnant women where ultrasound findings or family history raise single-gene disease concerns.
• VISTA™ Carrier Screening Test Preconception and prenatal genetic carrier screening panel offered in Mini (12 diseases), Target (172 diseases), and Max (1,231 diseases) tiers to identify recessive disease carrier status in couples planning or undergoing pregnancy.
• VISTA™ Chromosome Sequencing Chromosomal sequencing test using low-depth whole genome sequencing and short tandem repeat analysis to screen all 23 chromosome pairs for abnormalities associated with miscarriage, fetal defects, and infertility, targeting couples experiencing reproductive challenges.
• VISTA™ PGT-A Preimplantation Genetic Testing Preimplantation genetic testing for aneuploidy performed on embryos during IVF cycles using BGI's proprietary DNBSEQ™ single-cell whole genome sequencing, marketed to fertility clinics and IVF patients seeking embryo chromosomal screening.
• VISTA™ Thalassemia Gene Test Thalassemia gene test using multiplex PCR combined with next-generation sequencing to detect more than 508 thalassemia variants, sold to couples planning pregnancy in regions where thalassemia is prevalent.
• NOVA™ Newborn Genetic Screening Newborn genetic screening suite covering metabolic disease screening and hereditary deafness gene testing, used by Hong Kong hospitals and parents to detect treatable genetic conditions shortly after birth.
• Xome™ Clinical Whole Exome and Genome Sequencing Clinical whole exome, whole genome, and targeted-region sequencing services used by clinicians and patients seeking comprehensive genetic diagnosis for suspected single-gene diseases.
• SENTIS™ Hereditary Cancer Genetic Testing Panel Hereditary cancer screening panel covering 108 genes across 26 cancer types using peripheral blood or saliva samples, marketed to individuals with family cancer history and clinicians seeking hereditary cancer risk assessment and treatment guidance.
• SENTIS™ HPV Self-Sampling Test At-home HPV self-sampling test detecting 14 high-risk HPV virus types (including 16, 18 and 12 other high-risk genotypes) via nucleic acid testing, sold directly to consumers in Hong Kong for private cervical cancer risk assessment.
• COLOTECT™ Colorectal Cancer Self-Sampling Test Non-invasive colorectal cancer self-sampling test using multi-target stool DNA methylation detection (SDC2, ADHFE1, PPP2R5C markers) and multiplex methylation-specific PCR, sold directly to consumers and distributed via designated clinics in Hong Kong for at-home screening.
• Umeta Probiotic Nutrition Products Consumer probiotic nutrition brand developed by BGI using its global high-throughput genetic sequencing and bioinformatics platforms, offering chewable tablets and solid beverage SKUs targeted at different population groups and sold direct to consumer.

Quantifiable outcome

• 99% sensitivity and specificity for major trisomy detection (T21, T18, T13)
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• BGI Group (Parent Company)coreStrategic or Co-development Partner · 9 September 1999BGI Group established in 1999 is the parent company and global life science pioneer. BGI Health (HK) operates as a subsidiary, leveraging BGI's global network spanning 100+ countries and regions, 3000+ partner institutions, and proprietary technologies including DNBSEQ sequencing. The subsidiary serves as a bridge between overseas and mainland China markets.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Prenetics Group: Hong Kong-headquartered genetic testing and diagnostics company offering Circle HealthPod, non-invasive prenatal tests, and cancer screening. Directly competes with BGI Health HK in Hong Kong across NIPT and DTC cancer screening, with overlapping clinics and consumer channels in the same city.
• Natera Inc. US-based genetic testing company operating the Panorama NIPT, Empower carrier screen, and Signatera MRD oncology products. Competes head-to-head with NIFTY in NIPT markets and Signatera parallels BGI's MRD offerings.
• Myriad Genetics: Major US genetic testing company offering hereditary cancer panels (BRACAnalysis, myRisk), non-invasive prenatal screening, and tumor profiling. Direct NIPT and hereditary cancer overlap with BGI Health HK's NIFTY and SENTIS products.
• 23andMe Holding Co. Direct-to-consumer genetic testing company offering health and ancestry tests including carrier screening and hereditary cancer reports. Comparable consumer-driven genetic testing model and similar international aspirations to BGI Health HK's self-sampling strategy.
• Invitae (now Labcorp Genetics): Genetic testing company offering carrier screening, hereditary cancer panels, NIPT (via paired testing), and whole exome sequencing. Direct overlap with VISTA carrier, SENTIS cancer panels, and Xome exome products.
• Color Genomics: Genetic testing company offering hereditary cancer panels, NIPT-adjacent screening, and population health programs. Comparable model combining clinical-grade lab with employer/government health partnerships akin to BGI Health HK's SENTIS and Healthy Hong Kong initiatives.

Broad incumbents

• Illumina (Verinata / NIPT business): Through its Verinata Health acquisition, Illumina offers the verifi NIPT and is the dominant NGS platform supplier to many genetic testing labs globally. Competes with NIFTY while also enabling much of the broader NIPT industry.
• KingMed Diagnostics: China's largest independent third-party medical testing lab network with extensive prenatal, hereditary cancer, and infectious disease testing menu — a broader incumbent across the same diagnostic categories BGI Health HK competes in within Asia-Pacific.
• NeoGenomics Laboratories: US oncology-focused clinical laboratory offering comprehensive tumor profiling, hereditary cancer testing, and minimal residual disease (MRD) tests comparable to BGI's oncology and MRD product lines.

Regional players

• Sanomics / Codex Genetics (Hong Kong DNA testing companies): Hong Kong and Greater China regional genetic testing companies offering DTC ancestry and health-related genetic tests in the local market, competing for similar Hong Kong consumers seeking accessible genetic screening.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/bgi-health-hk-c%EF%BF%BDompany-limited

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BGI HEALTH (HK) C�OMPANY LIMITED